The FDA would receive $4.7 billion for its drug, medical device and biologic surveillance, an $821 million increase over 2012, under a budget proposal released by HHS for 2014. A total of $1.29 billion will go toward the FDA's drug program, $435 million for medtech and $338 million for biologics, which will be supplemented by the user fees paid for new product reviews.

Related Summaries